U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.89
    +0.18 (+0.39%)
     
  • Gold

    1,808.60
    +3.10 (+0.17%)
     
  • Silver

    23.45
    +0.09 (+0.38%)
     
  • EUR/USD

    1.1929
    +0.0010 (+0.0835%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3390
    +0.0007 (+0.0536%)
     
  • USD/JPY

    104.3080
    -0.1320 (-0.1264%)
     
  • BTC-USD

    17,779.03
    -890.35 (-4.77%)
     
  • CMC Crypto 200

    347.09
    -23.43 (-6.32%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,434.86
    +138.00 (+0.52%)
     

Alcon: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 15.22% year over year to $0.39, which beat the estimate of $0.22.

Revenue of $1,818,000,000 declined by 1.25% year over year, which beat the estimate of $1,670,000,000.

Outlook

Alcon hasn't issued any earnings guidance for the time being.

View more earnings on ALC

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $68.11

Company's 52-week low was at $39.37

Price action over last quarter: Up 11.13%

Company Description

Alcon, headquartered in Fort Worth, Texas, is the global eye care leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.